Prelude Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Prelude Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,100	Closed	-$210K	–	2278
2020 Q3	$210K	Buy	+6,100	New	+$130K	0.01%	676
2018 Q4	–	Sell	-2,000	Closed	-$55K	–	2320
2018 Q3	$55K	Buy	+2,000	New	+$56.6K	﹤0.01%	1114

Prelude Capital Management's AIMT Position: Q4 2020 in Review

Prelude Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 219,893 shares — an estimated $7.58M sold.

Prelude Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $7.58M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Prelude Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Prelude Capital Management sold 219,893 Aimmune Therapeutics shares in Q4 2020, an estimated $7.58M.
Prelude Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Prelude Capital Management's Aimmune Therapeutics position peaked at $7.58M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.